BioLife Solutions Granted European Biopreservation Patent
News Dec 10, 2008
BioLife Solutions, Inc. has announced that it has been granted a European patent for an application that includes claims related to protecting cells from injury and death caused by cold temperatures used in biopreservation. The patent titled, “Inclusion of Apoptotic Regulators in Solutions for Cell Storage at Low Temperature,” was previously granted US patent protection.
Mike Rice, BioLife’s chairman and CEO, noted that the new patent expands the protections of the Company’s key intellectual property related to regulating the biologic process of apoptosis in response to the accumulated stress due to exposure to hypothermic and freezing temperatures.
The new patent is a direct result of BioLife’s ongoing effort to increase the value of its intellectual property portfolio and enable additional product and licensing revenue streams for BioLife, he added.
“We’ve repeatedly shown via numerous internal and customer validations that our products better protect cells and tissues from the harmful necrotic and apoptotic effects of hypothermic storage, freezing, and thawing, and as a result, can extend the shelf life and improve the post preservation recovery, viability, and functional yield of both biologic source material as well as isolated cells,” Rice said, adding that the Company has submitted several additional patent applications during 2008.
Scientists have used machine learning to train computers to see parts of the cell the human eye cannot easily distinguish. Using 3D images of fluorescently labeled cells, the research team taught computers to find structures inside living cells without fluorescent labels, using only black and white images generated by an inexpensive technique known as brightfield microscopy.READ MORE
The National Institutes of Health announced the launch of a new initiative to help speed the development of cures for sickle cell disease. The Cure Sickle Cell Initiative will take advantage of the latest genetic discoveries and technological advances to move the most promising genetic-based curative therapies safely into clinical trials within five to 10 years.